ORMP - Oramed Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.0400
+0.0200 (+0.50%)
At close: 04:00PM EDT
4.0500 +0.01 (+0.25%)
After hours: 07:32PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close4.0200
Open3.9900
Bid0.0000 x 800
Ask0.0000 x 1200
Day's Range3.9500 - 4.2001
52 Week Range1.8100 - 13.7300
Volume557,123
Avg. Volume970,052
Market Cap161.711M
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-0.8100
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.77
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ORMP

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zacks Small Cap Research

    ORMP: Advancing Development Efforts in China

    By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Licensing deal – potential royalty payments if product is commercialized in China … Earlier this month, Oramed Pharmaceuticals’ (NASDAQ:ORMP) partner in China, Hefei Tianhui Biotechnology Co. (HTIT), completed a Phase 3 oral insulin clinical trial in China and, based on the results, submitted a marketing authorization application to

  • PR Newswire

    Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA, on May 31, 2023. The presentation will include an overview of Oramed's oral delivery technology as well as insights from the Company's recent Phase 3 oral insulin clinical trials.

  • PR Newswire

    Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) announced today that Hefei Tianhui Biotechnology Co. Ltd. (HTIT), a strategic partner of Oramed, has successfully completed its Phase 3 trials of oral insulin in type 2 diabetes in China under a differentiated study protocol. HTIT is now moving toward regulatory approval and has submitted the data to the National Medical Products Administration (NMPA, formerly the CFDA).

  • Bloomberg

    Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company

    (Bloomberg) -- Right-wing media entrepreneur Ben Shapiro has taken a $4.7 million stake in a struggling Israeli pharmaceutical company and joined the board.Most Read from BloombergNigeria Targeted a UK Mansion; Its Next Leader’s Son Now Owns ItWall Street Rattled by 15% Tumble in Pair of Banks: Markets WrapCarl Icahn’s Wealth Plunges $10 Billion on Hindenburg Short-Seller ReportIBM to Pause Hiring for Jobs That AI Could DoRegional Bank Shares Plunge on Fear of More Rescues to ComeShapiro, 39, a

  • PR Newswire

    Oramed Appoints Ben Shapiro to its Board of Directors

    Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market.

  • Simply Wall St.

    The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

    The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...

  • PR Newswire

    Oramed Pharmaceuticals Issues Shareholder Update

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials. In addition, management and the Board of Directors are examining the Company's existing pipeline and conducting a comprehensive review of strategic alternatives focused on enhancing shareholder value.

  • Zacks Small Cap Research

    ORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts

    By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals’ (NASDAQ:ORMP) recently released top-line results from its ORA-D-013-1 Phase 3 study comparing the efficacy of ORMD-0801 to placebo in patients with T2D (type 2 diabetes) at 26 weeks failed to meet primary and secondary endpoints. Oramed expects to discontinue its oral insulin clinical activities for T2D. This

  • Motley Fool

    Why Oramed Pharmaceuticals Stock Is Crashing Today

    The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.

  • Benzinga

    Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study

    Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced top-line results from its Phase 3 trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents. The ORA-D-013-1 trial did not meet its primary endpoint, which compared the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by the mean change from

  • PR Newswire

    Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

    Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering ag

  • Simply Wall St.

    Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • PR Newswire

    Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceu

  • PR Newswire

    Oramed Letter to Shareholders

    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

  • ACCESSWIRE

    Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022

    The Planet MicroCap Showcase: VIRTUAL taking place on December 6-8, 2022, where 49 MicroCap public companies will be presenting virtually.

  • PR Newswire

    Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled: "Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study," authored by Roy Eldor, MD PhD, Bruce H. Francis, MD, Alexander Fleming, MD, Joel Neutel, MD, Kenneth Homer, MS, Miri

  • Zacks Small Cap Research

    ORMP: Data from NASH Phase 2 Study – Positive Takeaways

    By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Data supports moving ahead with NASH clinical studies… Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has multiple clinical development programs underway. ORMD-0801, ORMP’s lead development candidate, is being tested in diabetes in dual concurrent Phase 3 studies of ORMD-0801 for the treatment of T2D and in NASH. We believe Oramed’s multiple

  • Benzinga

    Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study

    Oramed Pharmaceuticals Inc (NASDAQ: ORMP) has announced additional data from its Phase 2 trial (ORA-D-N02) of oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis (NASH). Overall, the Phase 2 trial proved that ORMD-0801 might be a potential candidate for reducing liver fat, stiffness, and lipids in patients with T2D and NASH. Related: Oramed Oral Insulin Shows Evidence For NASH Treatment. The whole Liver showed a placebo-ad

  • PR Newswire

    Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced additional positive data from its Phase 2 double-blind, fully randomized, placebo-controlled, multicenter clinical trial (ORA-D-N02) to assess the safety and efficacy of its oral insulin candidate (ORMD-0801), to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis ("NASH"). The presentation

  • Simply Wall St.

    Oramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

    Oramed Pharmaceuticals ( NASDAQ:ORMP ) Third Quarter 2022 Results Key Financial Results Net loss: US$7.06m (loss...

  • PR Newswire

    Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

    Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced it has signed an exclusive commercial distribution agreement for the Republic of Korea (formerly South Korea) with Medicox Co., Ltd., an emerging biotech company with an excellent consortium of proven partnerships in the Republic of Korea.

  • PR Newswire

    Oramed Reports Third Quarter 2022 Financial Results

    Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today reported its financial results for the quarter ended September 30, 2022.

  • PR Newswire

    Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it will host a data presentation on newly released safety and efficacy data from the Phase 2 trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes ("T2D") patients with non-alcoholic steatohepatitis ("NASH") on Thursday, November 17, 2022, at 11:00 a.m. Eastern St

  • Simply Wall St.

    Oramed Pharmaceuticals (NASDAQ:ORMP) shareholders have earned a 27% CAGR over the last three years

    While Oramed Pharmaceuticals Inc. ( NASDAQ:ORMP ) shareholders are probably generally happy, the stock hasn't had...

  • Benzinga

    Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study

    Oramed Pharmaceuticals Inc's (NASDAQ: ORMP) subsidiary, Oravax Medical Inc, reported preliminary data from its Phase 1 trial of an oral COVID-19 vaccine candidate. Preliminary Phase 1 trial results from the first cohort include: Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in most patients dosed. No safety issues were observed, including mild symptoms. An open-label, Phase 1 trial will evaluate the safe